LANGUAGE:
LANGUAGE:
Content Services
- Technical Writing
- Training & eLearning
- Financial Reports
- Digital Marketing
- SEO & Content Optimization
Translation Services
- Video Localization
- Software Localization
- Website Localization
- Translation for Regulated Companies
- Interpretation
- Instant Interpreter
- Live Events
- Language Quality Services
Testing Services
- Functional QA & Testing
- Compatibility Testing
- Interoperability Testing
- Performance Testing
- Accessibility Testing
- UX/CX Testing
Solutions
- Translation Service Models
- Machine Translation
- Smart Onboarding™
- Aurora AI Studio™
Our Knowledge Hubs
- Positive Patient Outcomes
- Modern Clinical Trial Solutions
- Future of Localization
- Innovation to Immunity
- COVID-19 Resource Center
- Disruption Series
- Patient Engagement
- Lionbridge Insights
Life Sciences
- Pharmaceutical
- Clinical
- Regulatory
- Post-Approval
- Corporate
- Medical Devices
- Validation and Clinical
- Regulatory
- Post-Authorization
- Corporate
Banking & Finance
Retail
Luxury
E-Commerce
Games
Automotive
Consumer Packaged Goods
Technology
Industrial Manufacturing
Legal Services
Travel & Hospitality
SELECT LANGUAGE:
This is the seventh piece in the Lionbridge Disruption Series, a collection of commentary from life sciences experts on how the industry is changing as a result of the COVID-19 crisis.
“It’s a small world.” How often have we heard others say this phrase (or said it ourselves)? The COVID-19 pandemic has certainly added a new angle to its meaning. The speed with which the virus has reached the most remote corners of the planet and the changes and challenges that it has created for individuals and whole countries have been astounding. Indeed, all that brought home the realisation that people are part of one big global family.
Around the world, this realisation is visible in the vigorous response and tremendous collaboration between the scientific, industry and regulatory communities. All these groups are uniting around a common goal: curing and preventing for COVID-19. The clinical research into this novel virus has expanded exponentially within a short period of time. It shows no sign of slowing, as is evidenced by the continuously growing number of clinical trials conducted in different countries.
Governments and regulators such as the FDA, EMA, MHRA, and PMDA, are taking action to expedite this research. Open communication, guidance documents and accelerated approval pathways are all aiding the progress towards possible therapies for COVID-19.
Patient participation remains central to the success of a clinical trial, no matter what disease or condition is the focus. Reports on patient health status outcomes, such as symptoms, functioning, tolerability and satisfaction with treatment, and health-related quality of life provide the researchers with valuable data. The resulting information concerning potential benefits and risks of the new treatment is then considered in regulatory decision-making.
Under normal circumstances, the strategies for the collection and processing of patient-reported outcome (PRO) and other clinical outcome assessment (COA) data in a clinical trial require thorough preparation, planning and implementation. The continuously evolving “new normal” is making it necessary for the drug development and clinical research industries to re-think and adapt those strategies.
The impact of the pandemic on the clinical trials has been wide ranging: from suspending the enrollment of new patients to early withdrawal of individual study participants to complete study halts. In many cases, the quarantine and social distancing measures have made on-site patient visits infeasible. Many clinical outcome assessments are typically administered during in-person visits to the trial site. As a result, the current disruption presents a number of challenges in maintaining continuity of data collection in a remote fashion:
These are only few of the many challenges. In addressing those, sponsors and trial sites have to consider legal, regulatory, ethical and scientific implications as well as practical and logistical aspects. In that respect, the recent update to the FDA’s March 2020 guidance offers helpful new content on conduct of remote COA assessments, with focus on the clinician-reported outcome or performance outcome assessments. Another valuable reference source is a presentation prepared by the Critical Path Institute’s PRO and ePRO consortia. This document presents a set of risk assessment and mitigation strategies for the collection of patient-reported outcome data in clinical trials through COVID-19.
Unquestionably, along with the acknowledgement that a certain level of flexibility and adjustments to clinical trials are necessary in light of the pandemic, the key message of all guidance documents is loud and clear: protecting the safety, welfare and rights of the trial participants remains paramount and non-negotiable.
The COVID-19 pandemic has offered us a glimpse into a different reality. A reality in which human contact and face-to-face interaction have to be carefully managed to safeguard lives. A reality in which the availability and application of innovative technologies matter as never before, not just to facilitate that management but also to ensure the progress of the scientific research.
The uptake of the eCOA/ePRO technologies in clinical trials had been continuously and steadily growing over the recent years. There is no doubt that this trend will remain in place post-pandemic due to the multiple benefits offered by these technologies, particularly their patient-centric capabilities and suitability for a remote model of clinical trial conduct. With that, one might also expect that further advancements in the regulatory environment prompted by the pandemic will soon make decentralised clinical trials a more common fixture on the clinical research landscape.
The pandemic has also acutely underscored the importance of truthful, transparent, and timely communication. With respect to COA assessments and clinicial trials that involve participants who speak multiple languages, that means translating and adapting such assessments and documentation with cultural competence and linguistic accuracy. Properly managing the nuances of communication serves to enhance data quality, improve regulatory compliance and acceptance, and bring products to markets faster. To achieve these goals, it is critical to work with a partner that has the linguistic quality, industry experience, and global operating model needed to support your COA activities: a partner like Lionbridge Life Sciences.